Agalimmune Ltd., a new biopharma company, has been founded by investment groups Loxbridge Research LLP and Animatrix Capital LLP to develop immunotherapeutics for the treatment of cancer, with a focus on solid tumors. Agalimmune, based in London and CA, will use funding to continue the translation of Agalimmune’s immunotherapeutic technology, Alphaject, licensed from the University of Massachusetts Medical School (UMMS). The Alphaject technology includes methods for treating solid tumors such t...